安井食品(603345.SH):定增申请获中证监核准批覆
格隆汇11月5日丨安井食品(603345.SH)公布,公司于2021年11月5日收到中国证监会出具的《关于核准福建安井食品股份有限公司非公开发行股票的批覆》(证监许可[2021]3419号),批覆的主要内容如下:
一、核准公司非公开发行不超过4888.4872万股新股,发生转增股本等情形导致总股本发生变化的,可相应调整本次发行数量。
二、本次发行股票应严格按照公司报送中国证监会的申请文件实施。
三、本批覆自核准发行之日起12个月内有效。
四、自核准发行之日起至本次股票发行结束前,公司如发生重大事项,应及时报吿中国证监会并按有关规定处理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.